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Introduction {#sec1}
============

Over the course of evolution, the catabolic pathways of [l]{.smallcaps}-tryptophan (Trp) and of [l]{.smallcaps}-arginine (Arg) have evolved to be primary regulatory nodes in the control of immune responses ([@bib21], [@bib37]). Trp, an essential amino acid for mammals, is a substrate for indoleamine 2,3-dioxygenase 1 (IDO1), which catalyzes the first, rate-limiting step in the kynurenine pathway, leading to Trp depletion and the production of a series of immunoregulatory molecules collectively known as kynurenines ([@bib25], [@bib35], [@bib50]). Both effects---namely, Trp starvation and kynurenine production---are involved in the conversion of naive CD4^+^ T cells into Foxp3^+^ regulatory T (Treg) cells ([@bib14], [@bib50]). Moreover, the main IDO1 catalytic product, [l]{.smallcaps}-kynurenine (Kyn), has immunoregulatory effects in the absence of Trp starvation, via activation of the Aryl hydrocarbon Receptor (AhR) ([@bib22], [@bib49]).

High IDO1 expression and catalytic activity occur in dendritic cells (DCs) in response to the cytokine interferon-γ (IFN-γ) ([@bib25]). In DCs stimulated with transforming growth factor β (TGF-β), IDO1 becomes instead phosphorylated in its immune-based inhibitory tyrosine motifs (ITIMs), so to mediate intracellular signaling events in a self-sustaining feedforward loop that leads to durable immunoregulatory effects ([@bib5], [@bib45], [@bib44], [@bib58]). The composite mode of action of IDO1 may well explain its being recognized as an authentic regulator of immunity under several physiopathologic conditions ([@bib40], [@bib50]).

Arg is a semi-essential amino acid, i.e., it is required by mammals only under special circumstances, such as immune responses. In immune cells, Arg is actively metabolized by arginase 1 (Arg1) or Arg2 to produce urea and [l]{.smallcaps}-ornithine (Orn) or it is used for protein biosynthesis ([@bib59]). Moreover, nitric oxide synthases use Arg to make nitric oxide---a key anti-microbial gas and signaling molecule---and [l]{.smallcaps}-citrulline ([@bib9]). Arg consumption by Arg1, rather than Arg2 or nitric oxide synthases, represents a well-known immunoregulatory mechanism exploited by M2 macrophages ([@bib37], [@bib54]), as well as myeloid-derived suppressor cells (MDSCs) in tumoral settings ([@bib17], [@bib32]). Conversely, the immunoregulatory role of catalytic products via Arg1 activity (urea and Orn) has been unclear ([@bib21]). T helper 2 (Th2) cytokines, such as interleukin-4 (IL-4) and IL-13, represent efficient inducers of Arg1 expression ([@bib17], [@bib32], [@bib54]), although TGF-β has also been shown to upregulate the enzyme, at least in rat peritoneal macrophages ([@bib8]). Besides its involvement in mouse dendritic cell (DC) differentiation ([@bib60]), the biology of Arg1 in DCs is still obscure. As a whole, the bulk of the data on Arg1 and IDO1 would suggest that the two amino-acid metabolic enzymes might operate in quite distinct spatial (i.e., cells) and mechanistic modes, namely via either amino acid starvation itself (as is the case for Arg1) or via the combined effects of immunoregulatory Kyn and signaling activity (IDO1). This suggests that the enzymes have separate functions (to possibly cope with distinct environmental needs) and/or have evolved to complement, rather than integrate, each other.

DCs integrate multiple signals and mechanisms in order to promote either adaptive immunity or immune tolerance in response to specific conditions, such as distinct types of cytokinic milieu ([@bib2], [@bib31]). By using the main cytokines capable of inducing those metabolic enzymes (i.e., IFN-γ, IL-4, and TGF-β), we here investigated whether Arg1 and IDO1 were co-expressed in DCs and what the functional meaning---if any---of their co-expression would be. We found that (1) TGF-β, but neither IL-4, IFN-γ, nor combination thereof, will induce both Arg1 and IDO1 in DCs, with Arg1 being upregulated before IDO1; (2) Arg1 activity is absolutely required for IDO1-dependent signaling events as initiated by TGF-β; (3) a polyamine---spermidine, resulting from Orn decarboxylation---can replace TGF-β in the activation of the Src kinase that phosphorylates IDO1 and trigger immunosuppressive IDO1 signaling; and (4) DCs can be conditioned by Arg1^+^ MDSCs to express an IDO1-dependent immunosuppressive phenotype.

Results {#sec2}
=======

TGF-β Induces Co-expression of Arg1 and IDO1 in DCs {#sec2.1}
---------------------------------------------------

We investigated the expression and catalytic activity of Arg1 and IDO1 in splenic CD11c^+^ DCs stimulated with IL-4 (i.e., the main Arg1 inducer), IFN-γ, or TGF-β, both of which are IDO1 inducers. Combinations of TGF-β and IL-4 or IFN-γ were also tested. In accordance with previous data ([@bib44]), transcript analysis at 3 and 18 hr of cytokine incubation revealed that both IFN-γ and TGF-β upregulated *Ido1* expression, with IFN-γ inducing the IDO1-encoding gene to a higher extent and more rapidly than TGF-β ([Figure 1](#fig1){ref-type="fig"}A). By contrast, IL-4 did not increase *Ido1*, but it did induce *Arg1* expression (\>7-fold increase at 3 hr of stimulation). No modulatory effect could be observed for IFN-γ on *Arg1* expression. In contrast, TGF-β upregulated *Arg1* in a more intense fashion and with faster kinetics than *Ido1*. Negligible transcript expression for *Arg2* and *Nos2* (coding for the inducible nitric oxide synthase) could be observed in either unstimulated or TGF-β-stimulated DCs (data not shown). DC incubation with TGF-β plus IL-4 resulted in a synergistic effect on *Arg1* upregulation (\>12- and 20-fold increase at 3 and 18 hr, respectively) but in no induction of *Ido1*. On combining TGF-β with IFN-γ, no incremental effect over that of IFN-γ alone was observed at 3 hr and impaired upregulation of *Ido1* expression by TGF-β would instead occur at 18 hr.

We next evaluated whether the differential modulation of Arg1 and IDO1 could also be observed at the level of protein expression and catalytic activity. Immunoblot analyses with anti-Arg1 and anti-IDO1 antibodies on lysates of DCs---subjected to the same treatments as in [Figure 1](#fig1){ref-type="fig"}A but for 24 hr---confirmed the real-time PCR experiments, i.e., IL-4 and IFN-γ induce only Arg1 and IDO1, respectively, whereas TGF-β alone, but not in combination with IL-4 or IFN-γ, upregulated protein expression of both enzymes ([Figure 1](#fig1){ref-type="fig"}B). Similarly, the enzymic activities of both Arg1 (measured in terms of urea contents in cell lysates; [Figure 1](#fig1){ref-type="fig"}C) and IDO1 (in terms of Kyn concentrations in culture supernatants; [Figure 1](#fig1){ref-type="fig"}D) were significantly upregulated at 24 hr by TGF-β but not IL-4, IFN-γ, or combinations thereof.

Therefore, these data showed that Arg1 can be expressed in DCs, specifically in response to IL-4 and/or TGF-β, and that Arg1 expression precedes that of IDO1 in DCs exposed to TGF-β alone. Perhaps more importantly, these data unveiled that the Arg and Trp catabolic pathways can be co-activated in DCs.

Arg1 Expression Is Required for IDO1 Induction by TGF-β in DCs {#sec2.2}
--------------------------------------------------------------

To better appreciate the temporal relationship between Arg1 and IDO1 expressions in TGF-β-stimulated DCs, we performed a more comprehensive kinetic analysis---i.e., from 0.5 to 72 hr of cytokine incubation---of transcripts coding for the two amino-acid catabolic enzymes. The results confirmed the earlier induction of *Arg1* (3−4 hr; [Figures 1](#fig1){ref-type="fig"}A and [2](#fig2){ref-type="fig"}A) as compared to *Ido1* transcripts (16−18 hr; [Figures 1](#fig1){ref-type="fig"}A and [2](#fig2){ref-type="fig"}A), as well as a higher extent of *Arg1* expression that peaked at 24−48 hr (\>7 fold increase as compared to unstimulated cells) of TGF-β stimulation. *Ido1* expression did not increase more than 3-fold ([Figure 2](#fig2){ref-type="fig"}A). Nevertheless, in agreement with our previous data ([@bib44]), the extent of *Ido1* expression remained stable throughout the experiment, i.e., up to 72 hr, after which DCs could no longer be analyzed because of poor viability. Conversely, *Arg1* transcripts appeared to decrease from 72 hr onward.

The sequential expressions of *Arg1* and *Ido1* prompted us to investigate whether Arg1 was required for IDO1 induction by TGF-β in DCs. We examined *Ido1* transcript amounts over time using DCs purified from the spleens of *Itgax-cre;Arg1*^*fl/fl*^ mice, lacking *Arg1* expression in CD11c^+^ (i.e., DCs) but not in CD11b^+^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}). We found that Arg1 deficiency abrogated *Ido1* induction by TGF-β but not by IFN-γ in DCs ([Figure 2](#fig2){ref-type="fig"}B). Analysis of IDO1 activity ([Figure 2](#fig2){ref-type="fig"}C) at 24 hr of TGF-β or IFN-γ stimulation also indicated that lack of Arg1 expression in DCs allowed IFN-γ but not TGF-β to upregulate IDO1. Thus these data identified a cytokine milieu whereby DCs exploit Arg1 expression to increase IDO1.

Orn Upregulates IDO1 in the Absence of Externally Added TGF-β {#sec2.3}
-------------------------------------------------------------

At variance with IDO1, which exerts immunoregulatory additional effects also via signaling activity ([@bib45], [@bib44], [@bib58]), Arg1-mediated mechanisms have been shown to occur only via Arg catalytic degradation. We thus investigated whether upregulation of *Ido1* transcripts in DCs by TGF-β could be modulated by N^ω^-hydroxy-nor-Arg (nor-NOHA), an inhibitor of arginases. Pre-incubation with 50 μM or 100 μM nor-NOHA for 1 hr prior to the addition of TGF-β significantly impaired the *Ido1*-inducing ability of the cytokine ([Figure 3](#fig3){ref-type="fig"}A), indicating a functional role for Arg1 catalytic activity in IDO1 modulation.

We next investigated whether Orn, an Arg1 product, was involved in *Ido1* upregulation. Incubation of DCs with Orn at 50 or 100 μM ([Figure 3](#fig3){ref-type="fig"}B) significantly increased *Ido1* expression, similar to what observed with the cytokine alone ([Figure 3](#fig3){ref-type="fig"}B). In contrast, no modulatory effect in *Ido1* expression could be observed in DCs stimulated with IFN-γ in the presence of the Arg1 inhibitor or Orn, both at 100 μM ([Figure 3](#fig3){ref-type="fig"}C). To evaluate whether autocrine and/or paracrine TGF-β could be involved in the *Ido1*-upregulating effects of Orn, WT DCs were incubated with the Arg metabolite for different times after a 1 hr pretreatment with an inhibitor of TGF-β receptor signaling, namely SB-431542, LY2109761, or LY2157299 (also known as galunisertib) ([Figure 3](#fig3){ref-type="fig"}D). DCs purified from transgenic CD11c^dnR^ mice (expressing a truncated form of TGF-β receptor II subunit in CD11c^+^ cells) ([@bib30]) were also assayed ([Figure 3](#fig3){ref-type="fig"}E). Both pharmacologic and genetic means of TGF-β signaling inhibition indicated that Orn effects do require autocrine and/or paracrine effects of TGF-β in both early inducing and late maintaining phase of *Ido1* expression (see also [Supplemental Text](#mmc1){ref-type="supplementary-material"}) and that the cytokine could be produced constitutively by DCs in basal conditions, in accordance to our previous data ([@bib3]).

In contrast to Orn, media deficient in Arg (4 and 40 μM in the place of standard 400 μM; [Figure 3](#fig3){ref-type="fig"}F) did not significantly increased *Ido1* expression. Moreover, Orn at 100 μM but not the use of an Arg-deficient medium (i.e., Arg at 4 μM) significantly increased IDO1 activity to an extent comparable to that observed with TGF-β ([Figure 3](#fig3){ref-type="fig"}G). Therefore, our data indicated that Orn, a main Arg1 product, but not Arg starvation, can condition DCs to upregulate IDO1 expression and activity if autocrine and/or paracrine TGF-β is present.

Orn Confers Immunosuppressive Properties on DCs via IDO1 Signaling {#sec2.4}
------------------------------------------------------------------

IDO1 immunosuppressive effects include non-enzymic functions, namely intracellular signaling events that, initiated by ITIM phosphorylation in the enzyme, are involved in reprogramming gene expression and in the induction of a stably regulatory phenotype in DCs ([@bib42], [@bib44]), capable of controlling T cell-mediated autoimmune responses ([@bib45], [@bib58]). In particular, IDO1's ITIM phosphorylation is triggered in DCs by TGF-β via a pathway that requires phosphatidylinositide 3-kinase (PI3K) and a tyrosine kinase of the Src family ([@bib5], [@bib58]), which phosphorylates IDO1 ITIMs. In turn, phosphorylated IDO1 ITIMs work as docking sites for tyrosine protein phosphatases, such as SHP-1 and SHP-2, which are concomitantly upregulated by TGF-β ([@bib42], [@bib44]). These events lead to the activation of an immunoregulatory signaling pathway in DCs that promotes endogenous production of TGF-β and induction of the *Ido1* gene, perpetuating IDO1 signaling events and associated immunosuppressive effects over the long term.

Because Orn was capable of upregulating *Ido1* in DCs in a sustained fashion comparable to that of TGF-β ([Figure 3](#fig3){ref-type="fig"}), we investigated whether Orn could replace the cytokine in activating the IDO1's signaling and immunosuppressive effects. By means of an antibody specific for the phosphorylated form of the enzyme ([@bib5], [@bib44], [@bib58]), we found that the DC incubation with Orn did induce IDO1 phosphorylation, with a peak at 15 min, i.e., an effect earlier than that triggered by TGF-β (at 30--60 min) ([Figure 4](#fig4){ref-type="fig"}A). Moreover, similarly to TGF-β, stimulation with the Arg1 product upregulated transcript expression of *Ptpn6* (coding for SHP-1) and *Tgfb1* at 18 hr in WT DCs. In contrast, no or less upregulation of *Ptpn6* and *Tgfb1*, respectively, was induced by TGF-β in *Itgax-cre;Arg1*^*fl/fl*^ DCs ([Figure 4](#fig4){ref-type="fig"}B), further confirming the important role of Arg1 in triggering and maintaining the IDO1 signaling.

To appreciate the immunosuppressive potential of DCs conditioned by Orn, we used the skin test assay, an established protocol for measuring the in vivo induction of antigen-specific immunoreactivity versus tolerance in DCs ([@bib23], [@bib26], [@bib44], [@bib51]). To this purpose, we sensitized wild-type (WT) mice with the HY peptide (containing the H-2D^b^ epitope of male minor transplantation antigen) presented by WT CD8^−^ DCs (constituting an immunostimulatory, splenic DC subset) ([@bib24]) administered alone or in combination with a minority fraction of the same cells (5%) purified from either WT or *Ido1*^*−/−*^ animals after conditioning with TGF-β, Orn, or medium alone for 24 hr. After priming the mice, we assessed immune reactivity at two weeks by intrafootpad challenge with the HY peptide in the absence of DCs, as described ([@bib23], [@bib26], [@bib44], [@bib51]). As expected, the default priming ability of immunostimulatory DCs was not affected by the presence of untreated cells. Yet, sensitization together with TGF-β- but also Orn-pretreated WT DCs caused suppression of HY-specific reactivity, an effect not detectable in mice sensitized with *Ido1*^*−/−*^ DCs, regardless of whichever type of conditioning molecule had been used ([Figure 4](#fig4){ref-type="fig"}C).

As a whole, our data indicated that the mere incubation of DCs with an Arg metabolite can activate molecular events traceable to IDO1 signaling as well as IDO1-dependent immunosuppressive outcomes detectable in vivo.

Orn Decarboxylation Is Required for Orn Effects Mediated by IDO1 in DCs {#sec2.5}
-----------------------------------------------------------------------

Orn can be further metabolized into putrescine, a polyamine that, in turn, can be transformed into spermidine and then spermine ([Figure S2](#mmc1){ref-type="supplementary-material"}), by Orn decarboxylase (ODC). In tumor cells, where it is often highly expressed, ODC favors proliferative events. More recently, ODC has been shown to be likewise involved in immunoregulatory mechanisms that oppose anti-tumor immunity ([@bib28]). As a matter of fact, administration of α-difluoromethylornithine (DFMO), an ODC inhibitor, will inhibit tumor growth via impairment of MDSC-mediated suppressive effects ([@bib61]). Whether DFMO-promoted immunity might also depend on impairment of IDO1 activity in DCs is currently unknown.

To evaluate ODC expression in DCs, we conducted a meta-analysis of public microarray data restricted to the expression of the *Odc1* gene in several mouse DC subsets purified from both lymphoid and nonlymphoid organs. The results showed that high amounts of *Odc1* transcripts were detectable in all DC subsets analyzed so far, including splenic, conventional CD11c^+^ DCs, the subject of the current study ([Figure 5](#fig5){ref-type="fig"}A). Prompted by these data, we investigated the effects of ODC inhibition on Orn actions in DCs. Because of the obligate requirement for ODC in many cell types ([@bib11], [@bib27]), we addressed this issue by using DFMO. We found that co-incubation of splenic DCs with Orn and DFMO abrogated the capacity of Orn alone to upregulate *Ido1* expression ([Figure 5](#fig5){ref-type="fig"}B). Moreover, by using the skin test assay as in [Figure 4](#fig4){ref-type="fig"}C, we found that no immunosuppressive effects could be conferred by Orn on WT DCs upon co-incubation of cells with DFMO ([Figure 5](#fig5){ref-type="fig"}C).

Because stimulation with Orn induced significant upregulation of the *IDO1* gene in human DCs as well, and DFMO negated this effect ([Figure S3](#mmc1){ref-type="supplementary-material"}), our data suggest that the ODC catalytic activity basally expressed in DCs exerts important immunoregulatory effects and that metabolites downstream of ODC function might represent the most proximal inducers of IDO1 signaling and IDO1-mediated immunosuppression in DCs.

Spermidine Activates the Src Kinase and Confers IDO1-Dependent, Immunosuppressive Properties in DCs {#sec2.6}
---------------------------------------------------------------------------------------------------

Polyamines, i.e., the diamine putrescine, the triamine spermidine, and the tetra-amine spermine, are highly bioactive polycations capable of binding nucleic acids and proteins and of modulating several signaling pathways. Polyamine functions have been studied most extensively in tumors, where they are often required for cell transformation and proliferation ([@bib18]). Whether polyamines can be produced by, or exert effects on, DCs is currently unknown.

Real-time PCR analyses revealed that DCs expressed high amounts of *Srm* and *Sms* genes, coding for spermidine and spermine synthase, respectively, and that such expression was not modulated by either TGF-β or IL-4 ([Figure S4](#mmc1){ref-type="supplementary-material"}A). To evaluate the effective production of polyamines by DCs, we assessed the profile of Arg metabolites along with that of Trp over time in culture supernatants of cells incubated with Orn ([Figure 6](#fig6){ref-type="fig"}A). Following Orn incubation, an increase was observed in DC release of all polyamines, with putrescine and spermidine production being evident at 4 hr and spermine at 16 hr. Moreover, Orn incubation also led to upregulation of IDO1 products, i.e., [l]{.smallcaps}-formylkynurenine at 4 hr, followed by [l]{.smallcaps}-kynurenine at 16 hr. An increase in other Orn metabolites (i.e., proline, [1]{.smallcaps}-pyrroline 4-hydroxy-2-carboxylate, γ-[l]{.smallcaps}-glutamyl-putrescine, and γ-[l]{.smallcaps}-glutamyl-amino-butyraldehyde) and Trp metabolites (serotonin, tryptamine, 5-hydroxy-[l]{.smallcaps}-tryptophan, and indole-3-acetaldehyde) could also be observed upon DC incubation with Orn.

We then compared the IDO1-inducing ability of polyamines with that of Orn in DCs. The results showed that DC incubation with either putrescine or spermidine for 24 hr significantly increased expression of the *Ido1* gene to an extent comparable to those induced by Orn ([Figure 6](#fig6){ref-type="fig"}B), whereas induction of the IDO1 protein could be observed only for spermidine ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In contrast, spermine did not upregulate IDO1 but rather showed a tendency to downregulate the enzyme expression ([Figure 6](#fig6){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}). In pro-inflammatory microenvironments, IDO1 is subjected to regulatory proteolysis mediated by the immunoproteasome in DCs ([@bib41]). We therefore investigated whether lack of IDO1 protein upregulation by putrescine could be due to a concomitant increase in immunoproteasome activity. We found that putrescine but not spermidine significantly upregulated *Psmb8*, *Psmb9*, and *Psmb10* transcripts, coding for β5i, β1i, and β2i immunoproteasome subunits, respectively, in DCs ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Moreover, we analyzed IDO1 protein expression in lysates from DCs exposed to cycloheximide (an inhibitor of protein synthesis) prior to incubation with putrescine alone or in combination with MG132, a proteasome inhibitor. These results revealed that, in the presence of cycloheximide, putrescine alone rather promoted a reduction in IDO1 protein expression, which was opposed by the co-presence of MG132 ([Figure S4](#mmc1){ref-type="supplementary-material"}D). The combination of MG132 and putrescine was accompanied by the appearance of proteins of higher molecular weight than 42 kDa, possibly representing polyubiquitinated IDO1 species, as described ([@bib41]).

In tumor cells, putrescine and spermidine but not spermine promote the phosphorylation and consequent activation of MAPK, Src, and PI3K (normally followed by Akt) kinases, via still undefined mechanisms ([@bib29]). Conversely, spermine has been shown to restrain immune responses in activated macrophages by inhibiting gene expression of NOS2 ([@bib64]). In intestinal epithelial cells, spermine negatively modulates the activity of Src kinase via direct binding of the Src SH2 domain ([@bib52]). Because Src is involved in the activation of IDO1 signaling in DCs ([@bib5], [@bib44], [@bib58]), we evaluated the ability of polyamines in modulating Src phosphorylation over time. Putrescine and spermidine, but not spermine, increased Src phosphorylation in DCs, as soon as at 5 min of cell incubation ([Figure 6](#fig6){ref-type="fig"}C). To conduct a more comprehensive evaluation of the potential of putrescine and spermidine in modulating signaling pathways in DCs, we performed a kinomic analysis using a microarray of peptides phosphorylable by tyrosine, serine, and threonine kinases ([@bib57]) and cell extracts from DCs incubated with the polyamines for 15 or 30 min. We found that putrescine is a potent activator of several kinases in DCs ([Figure S4](#mmc1){ref-type="supplementary-material"}E), including Src, Fyn, Hck, and Lck tyrosine kinases ([Table S1](#mmc1){ref-type="supplementary-material"}), and that it also promotes phosphorylation of a peptide from IKKβ, a kinase involved in the activation of the pro-inflammatory NF-κB pathway ([Table S4](#mmc2){ref-type="supplementary-material"}). Although less potent when considering the overall effect ([Figure S4](#mmc1){ref-type="supplementary-material"}E), spermidine did promote tyrosine phosphorylation of peptides from protein kinase C (ι type) and β-catenin, known substrates of Src and Fyn kinases ([Table S1](#mmc1){ref-type="supplementary-material"}), respectively, but not from IKKβ ([Table S4](#mmc2){ref-type="supplementary-material"}).

In a skin test assay, DC incubation with spermidine ([Figure 6](#fig6){ref-type="fig"}D) led to immunosuppressive effects detectable in vivo. Moreover, as observed for Orn ([Figure 4](#fig4){ref-type="fig"}C), spermidine effects were lost in *Ido1*^*−/−*^ DCs ([Figure 6](#fig6){ref-type="fig"}D). Importantly, the immunosuppressive effects were also impaired by coincubating WT DCs with spermidine and PP2 (a Src kinase inhibitor) but not PP3 (a negative control) ([Figure 6](#fig6){ref-type="fig"}D).

Overall, our data suggest that spermidine and its metabolic precursor putrescine are produced by DCs and represent major modulators of their own signaling pathways and function, including the activation of Src kinase. However, only spermidine triggered immunosuppressive IDO1 signaling, an effect possibly lost when using putrescine for DC conditioning because of the concomitant activation of several kinases other than those belonging in the Src family, including proinflammatory IKKβ, and because of the increased expression of proteasome subunits possibly degrading the IDO1 protein.

Arg1^+^ MDSCs Condition DCs toward an IDO1-Dependent, Immunosuppressive Phenotype {#sec2.7}
---------------------------------------------------------------------------------

As evident from their name, the defining feature of MDSCs is their ability to suppress immune cell functions. Main factors implicated in MDSC-mediated immune suppression include high expression of Arg1, among others ([@bib33]). In addition to their inherent immunosuppressive activity, MDSCs might amplify regulatory properties of other immune cells, particularly in tumor microenvironments. Although some mechanisms underlying MDSC-macrophage interaction have been established ([@bib56]), the cross-talk between MDSCs and DCs is still unclear ([@bib43]).

Prompted by the finding that an extracellular polyamine can condition DCs toward an IDO1-dependent, immunosuppressive phenotype, we investigated whether MDSCs could also exert similar effects on DCs via the Arg1 pathway. Arg1^+^ MDSCs were obtained from the bone marrow of WT mice as described ([@bib62]), pre-treated with nor-NOHA, DFMO (100 μM and 1 mM, respectively), or medium alone for 1 hr, extensively washed, and cocultured with DCs in separate chambers of transwells ([Figure 7](#fig7){ref-type="fig"}A). After 24 hr, DCs were recovered and analyzed for *Ido1* transcript expression by real-time PCR as well as immunosuppressive potential in vivo by skin test assay as in [Figure 4](#fig4){ref-type="fig"}C and [Figure 6](#fig6){ref-type="fig"}D. Controls included DCs cultured in transwells without MDSCs (medium; [Figure 7](#fig7){ref-type="fig"}A). We found that the separate coculture with untreated MDSCs significantly upregulated *Ido1* expression ([Figure 7](#fig7){ref-type="fig"}B) and conferred in vivo immunosuppressive properties on DCs ([Figure 7](#fig7){ref-type="fig"}C). However, both effects were lost when either Arg1 or ODC catalytic activity had been inhibited in MDSCs before their co-culturing with DCs. Moreover, no in vivo immunosuppressive phenotype could be acquired by *Ido1*^*−/−*^ DCs by conditioning with MDSCs not subjected to Arg1 or ODC inhibitor treatment ([Figure 7](#fig7){ref-type="fig"}C).

Thus our data confirmed that Arg and Trp immunoregulatory pathways are functionally integrated and that this integration can occur both intra- (i.e., DCs) and inter-cellularly (MDSCs and DCs) ([Figure S5](#mmc1){ref-type="supplementary-material"}A and [Figure 7](#fig7){ref-type="fig"}).

Discussion {#sec3}
==========

An effective communication networking represents the basis of life of evolved multicellular organisms. As a matter of fact, evidence for critical cross-talk mechanisms between metabolism and immunity---the main systems involved in maintaining and defending a constant internal milieu ([@bib39], [@bib47])---are emerging. In establishing adaptive immunometabolic networks over evolution, functional repurposing of ancestral proteins (originally only metabolic or immune in nature) may have represented a powerful strategy. Such evolved structures---defined as "moonlighting proteins" when they maintain their original function---often derive from gene duplication, a major driving force that renders biological systems more robust to environmental perturbations ([@bib13]).

Immune regulation is a highly evolved form of biologic response that controls immunity to self but also dampens exaggerated inflammation ([@bib15], [@bib16], [@bib21]). Metabolism of Arg and Trp and their consequent starvation in cell microenvironments still represent a survival strategy in phylogenetically ancient organisms. Yet, Arg and Trp catabolisms have been co-opted by immune regulation in mammals ([@bib37]). In this regard, the bulk of available information would suggest that the Arg1 enzyme, known to catabolize Arg mainly in immune cells such as MDSCs and macrophages, might have acquired immunoregulatory functions by "simply" extending the ancient mechanism of starvation to the control of activation and proliferation of T lymphocytes. This is even more true if one considers that, for instance, mouse macrophages stimulated with IL-4 will upregulate *Arg1* expression by 100- to 1,000-fold ([@bib46]). In contrast, in our study, the increase in *Arg1* transcripts in DCs incubated with IL-4 was no higher than 8-fold, suggesting that the Arg1 function in DCs might be considerably different as compared to the profound Arg starvation determined by Arg1^+^ macrophages. Nevertheless, the co-presence of IL-4 and TGF-β further upregulated *Arg1* transcripts more than 20-fold, suggesting that maximal expression of Arg catabolism would require multiple signals in DCs. In contrast, IDO1, the Trp catabolizing enzyme mainly operating in immune cells such as DCs, has been shown to exert immunoregulatory effects via Trp starvation but also via its catalytic products, i.e., kynurenines, and, perhaps most importantly, via a non-enzymic signaling activity ([@bib12], [@bib25], [@bib50]). In fact, by means of its ITIM domains (phosphorylable by Src tyrosine kinases activated in the presence of TGF-β), IDO1 establishes an intracellular signaling network in DCs that leads to the long-term expression of *Ido1* itself and subsequent, sustained control of adaptive immunity. At variance with *Arg1*, mouse *Ido1*, and human *IDO1* as well, might be the result of duplication of the more ancient *Ido2* (*IDO2* in humans) gene, an *Ido1* (*IDO1*) paralog characterized by low efficiency in Trp degradation and inability to act as a signaling molecule ([@bib42], [@bib63]). This represents the successful repurposing of a very ancient enzyme. Tryptophan 2,3-dioxygenase (TDO), another ancient enzyme mainly expressed in the liver and responsible for the degradation of Trp entered by diet, does not contain ITIMs.

We here showed that, in the presence of TGF-β but not IL-4, IFN-γ, or combinations thereof, Arg1 and IDO1 expressions co-exist in DCs. If anything, the co-presence of other cytokines rather impaired the TGF-β upregulating action on both amino-acid catabolizing enzymes, an effect possibly due the antagonistic effects of IL-4 ([@bib38]) and IFN-γ ([@bib9]) (G. Natoli, personal communication) on *Ido1* and *Arg1* gene expressions, respectively. The apparently transient, yet intense, induction of Arg1 enzymatic activity by TGF-β was mandatory for the subsequent IDO1 upregulation in terms of both catalytic and signaling mechanisms. These Arg1 effects were not mediated by Arg deprivation (as one might have expected, due to the poor or absent proliferative capacity of DCs) but rather by its downstream enzymatic catabolites, namely, the polyamine spermidine, generated downstream of decarboxylation of Orn, one of the direct Arg1 catalytic products. Moreover, our data indicated that this polyamine can promote IDO1 phosphorylation and signaling events in DCs ([@bib5], [@bib44], [@bib58]), possibly via direct activation of the Src kinase. Spermidine might therefore represent a two-sided node responsible for an intersection between the immunometabolic pathways of Arg1 and IDO1. Perhaps most importantly, this relay pathway would allow the immune system to translate an initial short-term (Arg1-mediated; typical of early-acting MDSCs and regulatory macrophages; [@bib19]) into a sustained regulatory response (via IDO1; typical of long-term acting tolerogenic DCs; [@bib36]).

TGF-β is a cytokine that appeared in metazoans and, by virtue of its marked pleiotropy and multiple effects, plays a prominent role in the logic of communicative networks in multicellular organisms ([@bib34]). Although the output of a TGF-β response is highly contextual, the presence of this cytokine in microenvironments often favors local immunosuppression, inhibiting anti-tumor immunity ([@bib20], [@bib48], [@bib55]). The TGF-β potential for inducing both enzymes, i.e., Arg1 in macrophages ([@bib8]) and IDO1 in DCs ([@bib4], [@bib44]) was already known. However, we here demonstrated that the immunoregulatory effects of TGF-β in DCs would go beyond the mutually exclusive upregulation of the Arg1 and IDO1 enzymes (observable in the presence of IL-4 and IFN-γ, respectively) by allowing the establishment of a network involving both Arg1 and IDO1 in DCs, further underlining the functional plasticity of these cells. Moreover, because MDSCs themselves are an abundant source of TGF-β production ([@bib6]), the network established by the triad constituted by TGF-β, Arg1, and IDO1 might be highly relevant to establishing potent immunosuppressive environments if also DCs are present as well.

In conclusion, our data, besides further underlining the importance of critical pathways linking metabolism and immunity in multicellular animals, suggest that the appearance of a highly evolved form of biologic response such as immune regulation would rely on a network based on the co-option of two ancient pathways, i.e., Arg and Trp catabolisms ([@bib1]) as reinforced by TGF-β. A consequence of this could be that tumors, considered to be the result of an evolutionary process ([@bib7]), have become particularly apt to co-opt metabolic and immunosuppressive networks to propel their generation and progression. Thus our data might predict that the simultaneous inhibition of two immune checkpoints such as Arg1 (<https://clinicaltrials.gov/show/NCT02903914>) and IDO1 ([@bib10]) could represent a successful strategy in tumor immunotherapy.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

Eight- to ten-week-old female C57BL/6 mice were obtained from Charles River Breeding Laboratories. *Ido1*^*−/−*^ mice were purchased from The Jackson Laboratory and bred at Charles River. To obtain *Itgax-cre;Arg*^*fl/fl*^ mice (i.e., lacking *Arg1* expression in CD11c^+^ cells), C57BL/6-Arg1^tm1Pmu/^J were bred to the strain C57BL/6J-Tg (*Itgax*-cre,-EGFP)4097Ach/J (The Jackson Laboratory), with inducible Cre recombinase expression in the CD11c^+^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}). CD11c^dnR^ mice on C57/BL6 background ([@bib30]) were bred and maintained at the animal facility of the University of Michigan School of Medicine.

Isolation and Treatments of DCs and MDSCs {#sec4.2}
-----------------------------------------

Splenic DCs were purified using CD11c MicroBeads (Miltenyi Biotec), as described ([@bib23]). Purity of DCs is detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. MDSCs were obtained from bone marrow cells, as previously described ([@bib62]). Details of MDSC purification and treatments can be found in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. For all in vitro studies, CD11c^+^ or CD8^−^ DCs were cultured at 1 × 10^6^ cells per well in 24-well plates in Iscove's Modified Dulbecco's medium (IMDM, Thermo Fisher Scientific) or, in selected experiments, in Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher Scientific), containing low or standard Arg levels (4, 40, or standard 400 μM) and completed by adding [l]{.smallcaps}-asparagine (120 μM) and [l]{.smallcaps}-lysine (790 μM). Recombinant human TGF-β (R&D System), Orn, and polyamines were used at the final concentration of 20 ng/ml, 50--100 μM, and 20 μM, respectively. In specific experiments, DCs were conditioned by co-culture for 24 hr with MDSCs (either such or pretreated for 1 hr with inhibitors) using transwell cell culture inserts (Nunc).

Real-Time RT-PCR, Western Blotting, and Determination of Arg1 and IDO1 Catalytic Activity {#sec4.3}
-----------------------------------------------------------------------------------------

All these procedures are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Arg1 protein expression was investigated in DCs by immunoblot with a goat polyclonal anti-mouse Arg1 antibody (Abcam). IDO1 and pIDO1 expressions were investigated with a rabbit monoclonal anti-mouse IDO1 antibody (cv152) ([@bib53]) or a rabbit polyclonal antibody to the phosphorylated ITIM1 motif of IDO1 ([@bib44]), respectively.

Immunization and Skin Test Assay {#sec4.4}
--------------------------------

A skin test assay was used for measurements of major histocompatibility complex class I--restricted delayed-type hypersensitivity (DTH) responses to the HY peptide (WMHHNMDLI) in C57BL/6 female recipient mice, as described ([@bib44]). For in vivo immunization, 3 × 10^5^ peptide-loaded CD8^−^ DCs, combined with a minority fraction (5%) of peptide-loaded C57BL/6 or *Ido1*^*−/−*^ CD8^−^ DCs, were injected subcutaneously into recipient mice. Two weeks later, a DTH response was measured to intrafootpad challenge with the eliciting peptide, and results were expressed as the increase in footpad weight of peptide-injected footpads over that of vehicle-injected (internal control) counterparts. The minority cell fraction, constituted by WT or *Ido1*^*−/−*^ CD8^−^ DCs, was left untreated or treated overnight with specific reagents as above.

Meta-analysis of DC Gene Expression Data, Metabolomic Analyses, and Kinome Profiling Analyses {#sec4.5}
---------------------------------------------------------------------------------------------

All these procedures are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analyses {#sec4.6}
--------------------

Unpaired Student's t test was used for in vitro analyses, using at least three values from 2--3 experiments per group, whereas for the skin test assay paired Student's t test was used (using at least six mice per group). Differences were considered significant with p \< 0.05.
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![Arg1 and IDO1 Are Co-expressed in DCs Stimulated with TGF-β\
(A) Real-time PCR analysis of *Arg1* and *Ido1* transcripts in DCs stimulated for 3 or 18 hr with IL-4, IFN-γ, TGF-β, IL-4 plus TGF-β, or IFN-γ plus TGF-β normalized to the expression of *Gapdh* (encoding glyceraldehyde phosphate dehydrogenase) and presented relative to results in untreated cells (dotted line, 1-fold).\
(B) Arg1 and IDO1 immunoblot analysis of cell lysates from DCs incubated with IL-4, IFN-γ, TGF-β, IL-4 plus TGF-β, IFN-γ plus TGF-β, or medium alone (untreated, unt) for 24 hr.\
(C) Arg1 and (D) IDO1 activity measured in terms of urea in cell lysates and [l]{.smallcaps}-kynurenine in cell supernatants, respectively, of DCs incubated as in (B).\
^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (Student's t test; cytokine-treated versus untreated samples). All data are from one experiment representative of three (A--D; means ± SD of triplicates in A, C, and D).](gr1){#fig1}

![Arg1 Expression Is Necessary for IDO1 Induction by TGF-β in DCs\
(A) Kinetic analysis of *Arg1* and *Ido1* transcripts in DCs from wild-type (WT) mice after incubation with TGF-β for different times (indicated).\
(B) Kinetic analysis of *Ido1* and *Arg1* transcripts in DCs from *Itgax-cre;Arg*^*fl/fl*^ animals prior to incubation with TGF-β or IFN-γ for different times. DCs from WT animals were used as control for IFN-γ stimulation. In (A) and (B), data are normalized and presented as in [Figure 1](#fig1){ref-type="fig"}A.\
(C) Kynurenine concentrations in supernatants of DCs from *Itgax-cre;Arg1*^*fl/fl*^ and WT animals incubated with TGF-β, IFN-γ, or medium alone for 24 hr.\
^∗^p \< 0.05; ^∗∗^p \< 0.01; and ^∗∗∗^p \< 0.001 (Student's t test; cytokine-treated versus untreated samples). All data are from one experiment representative of three (means ± SD of triplicates). Please see also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Orn Induces IDO1 Expression and Activity in DCs\
Kinetic analysis of *Ido1* transcripts in WT DCs stimulated with TGF-β (A and B), Orn (B and C), and/or IFN-γ (C) for different times (indicated) in the presence or absence of nor-NOHA (100 μM for IFN-γ), or medium with standard (i.e., 400 μM) or low (4--40 μM) Arg concentration (F).\
Kinetic analysis of *Ido1* transcripts in WT (D, E) or CD11^cdnR^ (E) DCs stimulated with Orn in the presence (D) or absence (E) of TGF-β receptor inhibitors. No toxic effects of inhibitors could be observed in DCs at the used concentration of 10 μM (data not shown).\
In (A)--(F), data are normalized and presented as in [Figure 1](#fig1){ref-type="fig"}A.\
(G) Kynurenine concentrations in supernatants of WT DCs stimulated with TGF-β in a standard medium (where not specified) or a medium with low Arg (4 μM), in the presence or absence of nor-NOHA (100 μM) or Orn (100 μM).\
^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (stimulated samples versus untreated controls). All data are from one experiment representative of three (means ± SD of triplicates).](gr3){#fig3}

![Orn Activates IDO1 Signaling and Confers IDO1-Dependent Immunosuppressive Properties in DCs\
(A) Immunoblot analysis of phosphorylated IDO1 (pIDO1) and total IDO1 in cell lysates of DCs incubated for different times with TGF-β or Orn (100 μM).\
(B) Real-time PCR analysis of *Ptpn6* and *Tgfb1* transcripts in WT DCs stimulated with TGF-β or Orn (100 μM) or in *Itgax-cre;Arg*^*fl/fl*^ DCs stimulated with TGF-β for 18 hr. Data are normalized and presented as in [Figure 1](#fig1){ref-type="fig"}A. ^∗^p \< 0.05 and ^∗∗^p \< 0.01 (unpaired Student's t test; cytokine- or Orn-treated versus untreated samples).\
(C) In vivo suppression of the activity of HY-pulsed WT CD8^−^ DCs into WT recipient mice, in combination with a minority fraction (5%) of CD8^−^ DCs from either WT or *Ido1*^*−/−*^ mice with no conditioning (unt, untreated) or conditioned in vitro with TGF-β or Orn (100 μM) for 24 hr; analysis of skin reactivity of recipient mice to the eliciting peptide at 15 days is presented as change in footpad weight. ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001 (paired Student's t test; mean weight of experimental versus control footpads). Data are from one experiment representative of two (A) or three (B and C; means ± SD of triplicates in B and six samples in C).](gr4){#fig4}

![Inhibition of Orn Decarboxylation Abrogates Orn Effects in DCs\
(A) Expression of *Odc1* transcripts in sub-populations of DCs derived from different tissues.\
(B) Kinetic analysis of *Ido1* transcripts in WT DCs stimulated with Orn (100 μM) in the presence or absence of 1 mM DFMO for different times (indicated). Data are normalized and presented as in [Figure 1](#fig1){ref-type="fig"}A. ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001 (unpaired Student's t test; Orn- or Orn plus DFMO-treated versus untreated samples).\
(C) In vivo suppression of the activity of HY-pulsed WT CD8^−^ DCs in combination with a minority fraction (5%) of the same cells with no conditioning (untreated, unt) or conditioned in vitro with Orn as in [Figure 4](#fig4){ref-type="fig"}C in the presence or absence of DFMO (1 mM); analysis of skin reactivity is as in [Figure 4](#fig4){ref-type="fig"}C. ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001 (paired Student's t test as in [Figure 4](#fig4){ref-type="fig"}C). Data are from one experiment representative of three (B and C; means ± SD of triplicates in B and six samples in C; means ± SD of samples indicated in [Table S3](#mmc2){ref-type="supplementary-material"} for each DC subset in A). Please see also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Spermidine Activates IDO1 Immunosuppressive Signaling\
(A) Analysis of Arg and Trp metabolite profiles in culture supernatants from DCs incubated with Orn (100 μM) for 4 or 16 hr. Results are expressed in terms of heatmap, in which each square represents the fold change in mass to charge ratio mean value of the relative metabolite as compared to time 0. Annotated targeted metabolites were derived from nontarget raw date and only represent signals of established chemical identities with 5 ppm.\
(B) Real-time PCR analysis of *Ido1* transcripts in DCs incubated with Orn, putrescine (Put), spermidine (Spd), or spermine (Spm; all at 20 μM) or medium alone for 24 hr. Data are normalized and presented as in [Figure 1](#fig1){ref-type="fig"}A. ^∗^p \< 0.05 and ^∗∗^p \< 0.01 (unpaired Student's t test; Orn- or polyamine-treated versus untreated samples).\
(C) Kinetics of Src phosphorylation in WT DCs incubated with Put, Spd, or Spm at 20 μM for different times. Cell lysates were analyzed by sequential immunoblotting with antibody to phosphorylated Src (pSrc), anti-Src, and β-tubulin.\
(D) In vivo suppression assay with a minority fraction (5%) of WT or *Ido1*^*−/−*^ CD8^−^ DCs with no conditioning (Unt) or conditioned in vitro with 20 μM spermidine in the presence or absence of PP2 or PP3 at 5 μM; analysis of skin reactivity is as in [Figure 4](#fig4){ref-type="fig"}C. ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001 (paired Student's t test as in [Figure 4](#fig4){ref-type="fig"}C). Data are from one experiment representative of two (A) and three (B--D; means ± SD of triplicates in B and six samples in D). Please see also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![MDSCs Confer DCs an IDO1-Dependent, Immunosuppressive Phenotype via Arg1 Metabolites\
(A) General scheme of transwell experiments. Purified MDSCs, expressing high amounts of Arg1 (data not shown), were pre-incubated for 1 hr with medium alone, nor-NOHA (100 μM), or DMFO (1 mM), prior to incubation with CD8^−^ DCs for 24 hr.\
(B) *Ido1* transcript expression in DCs conditioned as in (A). Data are normalized and presented as in [Figure 1](#fig1){ref-type="fig"}A. ^∗∗^p \< 0.01 (unpaired Student's t test; DCs conditioned with MDSCs alone or pretreated with enzyme inhibitors versus unconditioned DCs).\
(C) In vivo suppression as in [Figure 4](#fig4){ref-type="fig"}C with a minority fraction (5%) of WT or *Ido1*^*−/−*^ CD8^−^ DCs preconditioned in vitro in transwells for 24 hr with MDSCs preincubated as in (A); analysis of skin reactivity is as in [Figure 4](#fig4){ref-type="fig"}C. ^∗∗∗^p \< 0.001 (paired Student's t test as in [Figure 4](#fig4){ref-type="fig"}C). Data are from one experiment representative of three (B and C; means ± SD of triplicates in B and six samples in C). Please see also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
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